GTBP GT Biopharma, Inc. Stock Quote

GTBP [NASD]

Index	-	P/E	-	EPS (ttm)	-9.40	Insider Own	0.80%	Shs Outstand	28.39M	Perf Week	32.76%
Market Cap	417.86M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.00%	Shs Float	19.46M	Perf Month	65.20%
Income	-28.30M	PEG	-	EPS next Q	-0.24	Inst Own	8.00%	Short Float	6.26%	Perf Quarter	115.11%
Sales	-	P/S	-	EPS this Y	43.50%	Inst Trans	-	Short Ratio	1.86	Perf Half Y	373.24%
Book/sh	-12.29	P/B	-	EPS next Y	-3.10%	ROA	-	Target Price	23.00	Perf Year	593.39%
Cash/sh	0.20	P/C	78.84	EPS next 5Y	-	ROE	105.80%	52W Range	2.04 - 15.00	Perf YTD	123.22%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	7.27%	Beta	0.30
Dividend %	-	Quick Ratio	0.20	Sales past 5Y	-	Gross Margin	-	52W Low	688.07%	ATR	1.40
Employees	3	Current Ratio	0.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	82.96	Volatility	14.67% 14.01%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	2.20	Prev Close	14.92
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	656.38K	Price	16.09
Recom	2.00	SMA20	46.97%	SMA50	98.18%	SMA200	194.95%	Volume	1,444,027	Change	7.84%

Apr-13-21

Initiated

B. Riley Securities

Buy

$21

Mar-17-21

Initiated

ROTH Capital

Buy

$25

Apr-26-21 07:00AM	GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer PR Newswire
Apr-19-21 07:00AM	GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update PR Newswire -6.50%
Apr-12-21 08:00AM	GT Biopharma Announces GTB-3550 TriKE Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients PR Newswire
Apr-08-21 08:00AM	GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE Phase I/II Clinical Trial PR Newswire -9.75%
Mar-29-21 07:00AM	GT Biopharma's TriKE Interim Clinical Trial Results Presented At Innate Killer Summit 2021 PR Newswire
Mar-17-21 08:00AM	GT Biopharma Announces Updated Interim GTB-3550 Trike Clinical Trial Results PR Newswire
Mar-10-21 08:00AM	GT Biopharma to Present at The Virtual 33rd Annual Roth Conference PR Newswire
Mar-08-21 08:30AM	GT Biopharma Announces Preclinical Results For Its ROR1 TriKE As A Treatment For Prostate Cancer PR Newswire -7.35%
Mar-04-21 08:30AM	GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment PR Newswire -11.82%
Mar-02-21 03:00AM	Psyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1 Newsfile
Feb-18-21 08:00AM	GT Biopharma Transfers TriKE Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials PR Newswire
Feb-16-21 08:00AM	GT Biopharma Announces Closing of $23.7 Million Public Offering Business Wire +13.64%
Feb-11-21 08:00AM	GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market Business Wire -39.06%
Jan-19-21 09:00AM	GT Biopharma Appoints Two New Independent Directors PR Newswire -14.43%
Jan-12-21 10:00AM	GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550 PR Newswire
Jan-04-21 09:45AM	GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call PR Newswire
Dec-28-20 09:35AM	GT Biopharma Announces TriKE For The Treatment Of Breast And GI Cancers PR Newswire
Dec-21-20 11:00AM	GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT PR Newswire +12.58%
Dec-17-20 09:15AM	GT Biopharma And Cytovance Biologics Announce Milestone Achievement PR Newswire +5.08%
Dec-14-20 09:05AM	GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market PR Newswire +7.41%
Dec-08-20 07:30AM	GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients ACCESSWIRE +32.86%
Nov-18-20 07:30AM	GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer ACCESSWIRE
Nov-12-20 07:30AM	GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting ACCESSWIRE -5.41%
Oct-15-20 07:45AM	GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting ACCESSWIRE +17.50%
Oct-13-20 07:45AM	GT Biopharma Announces Advisory Board Appointments ACCESSWIRE -7.12%
Sep-22-20 07:45AM	GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update ACCESSWIRE
Aug-20-20 08:00AM	GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection ACCESSWIRE +5.41%
Aug-04-20 08:00AM	GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial ACCESSWIRE

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience